Skip to content

News

OCRFA Statement on Results of GOG 252

OCRFA Statement on Results of GOG 252

Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that the results of this … Continued

OCRFA Statement on Results of GOG 252

OCRFA Statement on Results of GOG 252

Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that the results of this … Continued

OCRFA Statement on Results of GOG 252

OCRFA Statement on Results of GOG 252

April 11, 2016 – Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group is that … Continued

Georgia Ovarian Cancer Alliance

Georgia Ovarian Cancer Alliance

The Georgia Ovarian Cancer Alliance (GOCA) formed back in 1998, when a group of thirteen ovarian cancer survivors from Atlanta met one another while undergoing chemotherapy. Through their conversations, many of them came to realize that prior to their own diagnosis they had never heard of the disease, or had even met an ovarian cancer … Continued

Research Update: Updated ICON6 Final Progression Free Survi...

Research Update: Updated ICON6 Final Progression Free Survival analysis

The Lancet has recently published an update to the progression-free survival (PFS) data of theICON6 trial.  (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.) ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled multi-center Gynaecologic Cancer InterGroup (GCIG) phase III trial.  ICON6 is designed to evaluate the safety and … Continued

Updated ICON6 Final Progression Free Survival analysis

Updated ICON6 Final Progression Free Survival analysis

(March 31, 2016) The Lancet has recently published an update to the progression-free survival (PFS) data of the ICON6 trial.  (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.) ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled multi-center Gynaecologic Cancer InterGroup (GCIG) phase III trial.  ICON6 is designed to … Continued

Research Updates from SGO Annual Meeting

Research Updates from SGO Annual Meeting

(March 30, 2016) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 19-22, 2016 in San Diego.  Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA … Continued

Highlights from the March 2016 Society of Gynecologic Oncol...

Highlights from the March 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

By: Annie Ellis, Ovarian Cancer Survivor and Research Advocate Women’s cancer specialists from all over the world convened in San Diego in March to hear about the latest developments in women’s cancer research. This was the fifth SGO annual meeting I’ve attended over the past eight years, and the first that I left with more confusion … Continued

Research Updates from SGO Annual Meeting

Research Updates from SGO Annual Meeting

OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 19-22, 2016 in San Diego.  Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA Research Advocate and … Continued

OCRFA Co-authors Paper on Educating about Hereditary Risk A...

OCRFA Co-authors Paper on Educating about Hereditary Risk Across Cancer Types

Ovarian Cancer Research Alliance today announced the online publication of a collaborative best practices paper entitled, “Understanding Hereditary Cancer in the Era of Multi-Gene Panel Testing.” The paper offers key insights into the changing needs of individuals and family members who might be at risk for hereditary cancer. The paper also includes discussion of how … Continued

Study Defines Characteristics of Long-Term Ovarian Cancer S...

Study Defines Characteristics of Long-Term Ovarian Cancer Survivors

(March 22, 2016) A new article in Gynecologic Oncology describes clinical features—some surprising—found in women surviving high-grade serous carcinoma for ten or more years. OCRF Scientific Advisory Committee member and former grantee Douglas A. Levine, MD was senior author of the paper. The study, a joint effort between five academic medical centers, examined 203 long-term … Continued

Q&A with OCRFA Grantee Jill Madden, Ph.D.

Q&A with OCRFA Grantee Jill Madden, Ph.D.

Q&A with Jill Madden, PhD University of Kansas Medical Center Research Institute, Inc. 2016 Ann Schreiber Mentored Investigator Award   OCRFA: Tell me about yourself. Did you always want to be a scientist? Were you interested in science as a child? Jill Madden: I grew up on a farm in rural Alden, Iowa, where livestock … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.